FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382025221> ?p ?o ?g. }

• W4382025221 abstract "Abstract Actinic keratoses (AK) are common in immunocompromised patients and associated with increased risk of cutaneous squamous cell carcinoma (cSCC). The current standard of care is 5-fluorouracil cream 5% (5-FU) monotherapy for 4 weeks. In recent years, 5-FU cream and calcipotriol ointment (5-FU-Cal) combination AK therapy for 4–6 days has emerged as potentially more effective and better tolerated, although the original randomized controlled trial (RCT) excluded immunosuppressed patients. Previously, we shared immunosuppressed patients’ real-world perspectives of using 5-FU monotherapy vs. 5-FU-Cal combination therapy (Junejo MH, Demirel S, Matin R et al. Short shock or slow burn? Patient perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy versus 5-fluorouracil plus calcipotriol combination therapy. Clin Exp Dermatol 2023; 48:31–2). The majority (81%) found 5-FU-Cal to be more effective than 5-FU monotherapy. Despite 47% reporting worse local skin reactions (LSRs), most preferred the 5-FU-Cal combination. We now report results from a clinician survey on the use of 5-FU monotherapy vs. 5-FU-Cal combination therapy for the treatment of AK. An online survey was sent to 200 UK consultant dermatologists. Fifty-seven (28.5%) completed the survey, all of whom reported using 5-FU monotherapy for treating AK in patients with prior cSCC; 43 (75%) reported this to be their preferred treatment. Most clinicians (n = 40; 70%) were aware of 5-FU-Cal combination therapy, although only 24 (42%) reported using it to treat AK in patients with prior cSCC. Of these, 18 (75%) used combination treatment for AK as part of field change, 14 (58%) used it for the treatment of patches of more than five AK and 13 (54%) used it for grouped AK. Very few (n = 4; 17%) used combination therapy for treatment of cSCC in situ (n = 4), single AK (n = 3) or superficial basal cell carcinoma (n = 1). Of 24 clinicians using 5-FU-Cal, the majority felt that patients developed LSRs often (n = 11; 46%) or always (n = 7; 29%); fewer felt that LSRs occurred sometimes (n = 5; 21%) or rarely (n = 1; 4%). Clinicians using combination therapy primarily felt the LSRs were moderate but not severe enough to require supplementary treatment or discontinuation (n = 17; 71%). Half (n = 12; 50%) of those using combination therapy felt patients did not signal a preference between 5-FU monotherapy vs. 5-FU-Cal combination therapy. Two-thirds (n = 38/57; 67%) of clinicians reported an interest in participating in a RCT comparing 5-FU vs. 5-FU-Cal vs. sunscreen alone for the treatment of AK in patients with prior cSCC. This is the first evaluation of clinician perspectives on the use of the newly emerging 5-FU-Cal therapy for AK. These data provide a rationale for the inclusion of combination 5-FU-Cal therapy in future studies using topical AK treatments for cSCC prevention in the UK." @default.
• W4382025221 created "2023-06-27" @default.
• W4382025221 creator A5002366186 @default.
• W4382025221 creator A5033609565 @default.
• W4382025221 creator A5043382789 @default.
• W4382025221 creator A5044662843 @default.
• W4382025221 creator A5047470313 @default.
• W4382025221 creator A5060867913 @default.
• W4382025221 creator A5069947870 @default.
• W4382025221 date "2023-06-01" @default.
• W4382025221 modified "2023-09-24" @default.
• W4382025221 title "BI06 Short sharp shock or slow burn: clinician perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy vs. 5-fluorouracil/calcipotriol ointment combination therapy" @default.
• W4382025221 doi "https://doi.org/10.1093/bjd/ljad113.174" @default.
• W4382025221 hasPublicationYear "2023" @default.
• W4382025221 type Work @default.
• W4382025221 citedByCount "0" @default.
• W4382025221 crossrefType "journal-article" @default.
• W4382025221 hasAuthorship W4382025221A5002366186 @default.
• W4382025221 hasAuthorship W4382025221A5033609565 @default.
• W4382025221 hasAuthorship W4382025221A5043382789 @default.
• W4382025221 hasAuthorship W4382025221A5044662843 @default.
• W4382025221 hasAuthorship W4382025221A5047470313 @default.
• W4382025221 hasAuthorship W4382025221A5060867913 @default.
• W4382025221 hasAuthorship W4382025221A5069947870 @default.
• W4382025221 hasBestOaLocation W43820252211 @default.
• W4382025221 hasConcept C126322002 @default.
• W4382025221 hasConcept C16005928 @default.
• W4382025221 hasConcept C168563851 @default.
• W4382025221 hasConcept C2776009542 @default.
• W4382025221 hasConcept C2776694085 @default.
• W4382025221 hasConcept C2776999253 @default.
• W4382025221 hasConcept C2780456651 @default.
• W4382025221 hasConcept C2780564577 @default.
• W4382025221 hasConcept C2910086692 @default.
• W4382025221 hasConcept C3019992690 @default.
• W4382025221 hasConcept C71924100 @default.
• W4382025221 hasConceptScore W4382025221C126322002 @default.
• W4382025221 hasConceptScore W4382025221C16005928 @default.
• W4382025221 hasConceptScore W4382025221C168563851 @default.
• W4382025221 hasConceptScore W4382025221C2776009542 @default.
• W4382025221 hasConceptScore W4382025221C2776694085 @default.
• W4382025221 hasConceptScore W4382025221C2776999253 @default.
• W4382025221 hasConceptScore W4382025221C2780456651 @default.
• W4382025221 hasConceptScore W4382025221C2780564577 @default.
• W4382025221 hasConceptScore W4382025221C2910086692 @default.
• W4382025221 hasConceptScore W4382025221C3019992690 @default.
• W4382025221 hasConceptScore W4382025221C71924100 @default.
• W4382025221 hasIssue "Supplement_4" @default.
• W4382025221 hasLocation W43820252211 @default.
• W4382025221 hasOpenAccess W4382025221 @default.
• W4382025221 hasPrimaryLocation W43820252211 @default.
• W4382025221 hasRelatedWork W2433992174 @default.
• W4382025221 hasRelatedWork W28058393 @default.
• W4382025221 hasRelatedWork W2924660264 @default.
• W4382025221 hasRelatedWork W3040800847 @default.
• W4382025221 hasRelatedWork W3108389004 @default.
• W4382025221 hasRelatedWork W3192924784 @default.
• W4382025221 hasRelatedWork W4210547956 @default.
• W4382025221 hasRelatedWork W4226324074 @default.
• W4382025221 hasRelatedWork W4283824668 @default.
• W4382025221 hasRelatedWork W4317565573 @default.
• W4382025221 hasVolume "188" @default.
• W4382025221 isParatext "false" @default.
• W4382025221 isRetracted "false" @default.
• W4382025221 workType "article" @default.